Literature DB >> 24746228

Molecular factors in dendritic cell responses to adsorbed glycoconjugates.

Nathan A Hotaling1, Richard D Cummings2, Daniel M Ratner3, Julia E Babensee4.   

Abstract

Carbohydrates and glycoconjugates have been shown to exert pro-inflammatory effects on the dendritic cells (DCs), supporting pathogen-induced innate immunity and antigen processing, as well as immunosuppressive effects in the tolerance to self-proteins. Additionally, the innate inflammatory response to implanted biomaterials has been hypothesized to be mediated by inflammatory cells interacting with adsorbed proteins, many of which are glycosylated. However, the molecular factors relevant for surface displayed glycoconjugate modulation of dendritic cell (DC) phenotype are unknown. Thus, in this study, a model system was developed to establish the role of glycan composition, density, and carrier cationization state on DC response. Thiol modified glycans were covalently bound to a model protein carrier, maleimide functionalized bovine serum albumin (BSA), and the number of glycans per BSA modulated. Additionally, the carrier isoelectric point was scaled from a pI of ∼4.0 to ∼10.0 using ethylenediamine (EDA). The DC response to the neoglycoconjugates adsorbed to wells of a 384-well plate was determined via a high throughput assay. The underlying trends in DC phenotype in relation to conjugate properties were elucidated via multivariate general linear models. It was found that glycoconjugates with more than 20 glycans per carrier had the greatest impact on the pro-inflammatory response from DCs, followed by conjugates having an isoelectric point above 9.5. Surfaces displaying terminal α1-2 linked mannose structures were able to increase the inflammatory DC response to a greater extent than did any other terminal glycan structure. The results herein can be applied to inform the design of the next generation of combination products and biomaterials for use in future vaccines and implanted materials.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Dendritic cells; Glycoconjugates; High throughput; Immunomodulation

Mesh:

Substances:

Year:  2014        PMID: 24746228      PMCID: PMC4127877          DOI: 10.1016/j.biomaterials.2014.03.048

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  58 in total

Review 1.  C-type lectin receptors on dendritic cells and Langerhans cells.

Authors:  Carl G Figdor; Yvette van Kooyk; Gosse J Adema
Journal:  Nat Rev Immunol       Date:  2002-02       Impact factor: 53.106

Review 2.  Tolerogenic dendritic cells.

Authors:  Ralph M Steinman; Daniel Hawiger; Michel C Nussenzweig
Journal:  Annu Rev Immunol       Date:  2001-12-19       Impact factor: 28.527

3.  Activation of lysosomal function during dendritic cell maturation.

Authors:  E Sergio Trombetta; Melanie Ebersold; Wendy Garrett; Marc Pypaert; Ira Mellman
Journal:  Science       Date:  2003-02-28       Impact factor: 47.728

4.  Structural basis for distinct ligand-binding and targeting properties of the receptors DC-SIGN and DC-SIGNR.

Authors:  Yuan Guo; Hadar Feinberg; Edward Conroy; Daniel A Mitchell; Richard Alvarez; Ola Blixt; Maureen E Taylor; William I Weis; Kurt Drickamer
Journal:  Nat Struct Mol Biol       Date:  2004-06-13       Impact factor: 15.369

Review 5.  Self- and nonself-recognition by C-type lectins on dendritic cells.

Authors:  Teunis B H Geijtenbeek; Sandra J van Vliet; Anneke Engering; Bert A 't Hart; Yvette van Kooyk
Journal:  Annu Rev Immunol       Date:  2004       Impact factor: 28.527

6.  Probing protein-carbohydrate interactions with microarrays of synthetic oligosaccharides.

Authors:  Daniel M Ratner; Eddie W Adams; Jing Su; Barry R O'Keefe; Milan Mrksich; Peter H Seeberger
Journal:  Chembiochem       Date:  2004-03-05       Impact factor: 3.164

Review 7.  Endogenous lectins shape the function of dendritic cells and tailor adaptive immunity: mechanisms and biomedical applications.

Authors:  Iván D Mascanfroni; Juan P Cerliani; Sebastián Dergan-Dylon; Diego O Croci; Juan M Ilarregui; Gabriel A Rabinovich
Journal:  Int Immunopharmacol       Date:  2011-02-04       Impact factor: 4.932

8.  High expression of ILT3 and ILT4 is a general feature of tolerogenic dendritic cells.

Authors:  John S Manavalan; Paola C Rossi; George Vlad; Flavia Piazza; Anna Yarilina; Raffaello Cortesini; Donna Mancini; Nicole Suciu-Foca
Journal:  Transpl Immunol       Date:  2003 Jul-Sep       Impact factor: 1.708

9.  Ligand-specific targeting of microspheres to phagocytes by surface modification with poly(L-lysine)-grafted poly(ethylene glycol) conjugate.

Authors:  Sofia Faraasen; János Vörös; Gábor Csúcs; Marcus Textor; Hans P Merkle; Elke Walter
Journal:  Pharm Res       Date:  2003-02       Impact factor: 4.200

10.  Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance.

Authors:  Laura Bonifaz; David Bonnyay; Karsten Mahnke; Miguel Rivera; Michel C Nussenzweig; Ralph M Steinman
Journal:  J Exp Med       Date:  2002-12-16       Impact factor: 14.307

View more
  4 in total

1.  Presentation Modality of Glycoconjugates Modulates Dendritic Cell Phenotype.

Authors:  N A Hotaling; D M Ratner; R D Cummings; J E Babensee
Journal:  Biomater Sci       Date:  2014-10-01       Impact factor: 6.843

Review 2.  Glycomaterials for probing host-pathogen interactions and the immune response.

Authors:  Mia L Huang; Christopher J Fisher; Kamil Godula
Journal:  Exp Biol Med (Maywood)       Date:  2016-05-04

Review 3.  The roles of galectins in parasitic infections.

Authors:  Weikun Shi; Chunyu Xue; Xin-Zhuan Su; Fangli Lu
Journal:  Acta Trop       Date:  2017-10-03       Impact factor: 3.112

Review 4.  Biomaterial Strategies for Immunomodulation.

Authors:  Nathan A Hotaling; Li Tang; Darrell J Irvine; Julia E Babensee
Journal:  Annu Rev Biomed Eng       Date:  2015-09-29       Impact factor: 9.590

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.